EXACT Sciences (EXAS) Upgraded to C- by TheStreet

TheStreet upgraded shares of EXACT Sciences (NASDAQ:EXAS) from a d rating to a c- rating in a research note issued to investors on Tuesday.

Other analysts have also issued reports about the stock. Benchmark reiterated a hold rating on shares of EXACT Sciences in a research report on Wednesday, September 5th. Cowen increased their price target on shares of EXACT Sciences from $65.00 to $100.00 and gave the company an outperform rating in a research report on Wednesday, September 5th. BidaskClub lowered shares of EXACT Sciences from a buy rating to a hold rating in a research report on Thursday, July 26th. Craig Hallum increased their price target on shares of EXACT Sciences from $54.00 to $74.00 and gave the company a buy rating in a research report on Thursday, August 23rd. Finally, Zacks Investment Research upgraded shares of EXACT Sciences from a sell rating to a hold rating in a research report on Tuesday, August 21st. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. EXACT Sciences has a consensus rating of Buy and an average target price of $84.08.

Shares of EXAS opened at $74.62 on Tuesday. The company has a current ratio of 12.08, a quick ratio of 11.72 and a debt-to-equity ratio of 0.94. EXACT Sciences has a twelve month low of $37.36 and a twelve month high of $81.22. The stock has a market cap of $9.12 billion, a price-to-earnings ratio of -75.37 and a beta of 1.21.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. The company had revenue of $118.29 million for the quarter, compared to analyst estimates of $109.33 million. During the same period in the prior year, the business posted ($0.23) earnings per share. The firm’s revenue for the quarter was up 63.0% compared to the same quarter last year. Equities analysts anticipate that EXACT Sciences will post -1.53 EPS for the current year.

In related news, Director Michael S. Wyzga sold 2,468 shares of the company’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $74.85, for a total transaction of $184,729.80. Following the transaction, the director now owns 9,112 shares of the company’s stock, valued at $682,033.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider D Scott Coward sold 2,190 shares of the company’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $79.51, for a total transaction of $174,126.90. The disclosure for this sale can be found here. Insiders have sold 218,255 shares of company stock worth $15,791,740 in the last three months. Insiders own 3.20% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in EXAS. First Trust Advisors LP lifted its stake in shares of EXACT Sciences by 6,220.7% during the third quarter. First Trust Advisors LP now owns 524,744 shares of the medical research company’s stock valued at $41,413,000 after buying an additional 516,442 shares during the period. CIBC Private Wealth Group LLC lifted its stake in shares of EXACT Sciences by 76.9% during the second quarter. CIBC Private Wealth Group LLC now owns 1,107,136 shares of the medical research company’s stock valued at $66,196,000 after buying an additional 481,230 shares during the period. Frontier Capital Management Co. LLC lifted its stake in shares of EXACT Sciences by 37.7% during the third quarter. Frontier Capital Management Co. LLC now owns 1,585,851 shares of the medical research company’s stock valued at $125,155,000 after buying an additional 434,184 shares during the period. Eagle Asset Management Inc. raised its stake in EXACT Sciences by 46.3% during the third quarter. Eagle Asset Management Inc. now owns 1,227,683 shares of the medical research company’s stock worth $96,888,000 after purchasing an additional 388,434 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in EXACT Sciences by 25.8% during the second quarter. Artisan Partners Limited Partnership now owns 1,879,525 shares of the medical research company’s stock worth $112,377,000 after purchasing an additional 385,766 shares during the period. 87.06% of the stock is currently owned by institutional investors and hedge funds.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Recommended Story: What does RSI mean?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply